BioLine RX Ltd represents values of innovation, collaboration, and commitment to improving patients' lives. The company believes in developing novel therapeutics and innovative solutions to address unmet medical needs. BioLine RX Ltd is dedicated to enhancing the quality of life for patients by advancing its diverse pipeline of potential medications. With a focus on partnerships and collaborations, BioLine RX Ltd aims to leverage its resources and expertise to bring promising therapies to market. By prioritizing patient outcomes and maintaining a patient-centric approach, BioLine RX Ltd strives to make a positive impact in the healthcare industry.

BioLine RX Ltd primarily operates in Israel, its home country. With headquarters in Modi'in, the company focuses on developing and commercializing novel therapeutics for various medical fields. Primarily present in Israel, BioLine RX Ltd leverages its expertise and collaborates with global partners to advance its pipeline and enhance the potential for successful treatments. By concentrating on its domestic market and fostering international collaborations, BioLine RX Ltd aims to deliver innovative solutions and contribute to improving global healthcare outcomes.

BioLine RX Ltd, a leading biopharmaceutical company, has achieved several significant milestones. Notably, the company successfully completed a Phase 2 clinical trial for its BL-8040 drug, demonstrating its potential as a treatment for acute myeloid leukemia (AML) and other hematological malignancies. Furthermore, BioLine RX Ltd has advanced its promising product pipeline, including the initiation of various clinical trials and collaborations with renowned research institutions. The company's commitment to innovation and dedication to improving patient outcomes have positioned BioLine RX Ltd as a key player in the biopharmaceutical industry, with great potential for growth and success in the future.

BioLine RX Ltd is a renowned biopharmaceutical company specializing in the development of novel therapeutics. Established in 2003, BioLine RX has been dedicated to advancing innovative drugs for various medical conditions. The company focuses on identifying promising research and forming strategic collaborations to bring effective treatments to the market. With a strong pipeline of potential therapies, BioLine RX aims to address unmet medical needs in areas such as oncology, immunology, and more. Committed to making a significant impact on patients' lives, BioLine RX continues to be a key player in the biopharmaceutical industry.

The main competitors of BioLine RX Ltd in the market include companies such as Pfizer Inc., Merck & Co., Inc., Novartis International AG, and Moderna, Inc.

BioLine RX Ltd is primarily active in the biotechnology and pharmaceutical industries. They specialize in developing and commercializing novel drugs for various medical conditions. With a focus on oncology, immunology, and infectious diseases, BioLine RX Ltd aims to provide innovative and effective therapeutic solutions. Through their extensive research and development efforts, they strive to improve patient outcomes and address unmet medical needs. As a reputable player in the biotech and pharmaceutical sectors, BioLine RX Ltd continues to drive advancements in healthcare with its cutting-edge drug development pipeline.

BioLine RX Ltd is a biopharmaceutical company focused on the development and commercialization of novel therapeutics. Their business model revolves around identifying promising technologies and advancing them through preclinical and clinical stages. By collaborating with leading academic institutions and strategic partners, BioLine RX aims to generate a diverse and innovative pipeline of products targeting unmet medical needs. This Israeli-based company is committed to leveraging its expertise in drug development and strategic relationships to bring novel therapeutics to market, thereby improving patients' lives and delivering value to its shareholders.

Il P/E per BioLine RX non può essere attualmente calcolato.

L'indicatore Price-to-Sales (KUV) per BioLine RX non può essere calcolato al momento.

Il Quality Score AlleAktien per BioLine RX è 4/10.

Il fatturato non può essere attualmente calcolato per BioLine RX.

Il profitto per BioLine RX non può essere attualmente calcolato.

BioLine RX Ltd. is an emerging biotechnology company specializing in the development and commercialization of novel therapeutic approaches for severe diseases. The company was founded in 2003 and is headquartered in Jerusalem, Israel. It has experienced significant growth in recent years and is currently listed on the NASDAQ and the Tel Aviv Stock Exchange. BioLine RX is divided into various business segments focused on the development and commercialization of innovative therapeutic approaches. The first area is clinical research, which is focused on developing drugs for the treatment of cancer, autoimmune diseases, and inflammatory diseases such as diabetes and rheumatism. The second area of the company is preclinical research, which focuses on the identification and validation of novel compounds and targets. In addition to these two core areas, BioLine RX also engages in partnerships with other companies and institutions to create synergies and collaborations in the development of new therapeutic approaches. BioLine RX has developed a range of products and therapeutic approaches based on novel technologies. One important product is BL-8040, a fusion protein aimed at the treatment of leukemia and other types of cancer. BL-8040 works by selectively recognizing tumor cells and inducing programmed cell death (apoptosis). The effectiveness of BL-8040 has been demonstrated in various phase 2 studies on patients, and BioLine RX plans to conduct further clinical trials to evaluate the efficacy of the drug. Another important product is BL-7010, a polymer developed as a treatment for celiac disease. Celiac disease is an autoimmune disorder that leads to inflammation of the small intestine and is triggered by gluten. BL-7010 works by binding gluten molecules in the intestine, thereby preventing the initiation of an immune reaction. The effectiveness of BL-7010 has been demonstrated in preclinical studies and in a phase 1 study on healthy volunteers, and BioLine RX plans to conduct further clinical trials to evaluate the efficacy of the drug. To promote the commercialization of its products and therapeutic approaches, BioLine RX has entered into partnerships with various companies and institutions. One important partnership is the collaboration with Novartis, a leading company in the pharmaceutical industry. Under this partnership, BioLine RX works with Novartis to develop and commercialize new cancer drugs. Overall, BioLine RX has developed a promising business model based on the research and commercialization of novel therapeutic approaches. With a strong focus on clinical and preclinical research, as well as partnerships with other companies and institutions, BioLine RX is expected to continue to be a major player in the biotechnology industry.

BioLine RX distribuisce un dividendo di 0 USD suddiviso in pagamenti all'anno.

La dividendazione per BioLine RX non può essere attualmente calcolata oppure la società non distribuisce dividendi.

La ISIN di BioLine RX è IL0011015182.

Il ticker di BioLine RX è BLRX.TA.

Nell'ultimo anno, BioLine RX ha pagato un dividendo di . Questo corrisponde a un rendimento da dividendo di circa . Per i prossimi 12 mesi, BioLine RX prevede di pagare un dividendo di 0 USD.

La resa dei dividendi di BioLine RX è attualmente del .

BioLine RX paga un dividendo su base trimestrale. Questo viene distribuito nei mesi di .

BioLine RX ha pagato un dividendo ogni anno negli ultimi 0 anni.

Nei prossimi 12 mesi si prevedono dividendi per un importo di 0 USD. Questo corrisponde a un rendimento da dividendo del 0 %.

BioLine RX è assegnato al settore 'Salute'.

Per ricevere l'ultima dividend of BioLine RX del 22/07/2024 dell'importo di 0 USD, dovevi avere l'azione in portafoglio prima del giorno "Ex" il 22/07/2024.

La distribuzione dell'ultima dividenda è avvenuta il 22/07/2024.

Nell'anno 2023 sono stati distribuiti da BioLine RX 0 USD come dividendi.

Le dividende di BioLine RX vengono distribuite in USD.